Evidence map›Paper›PMID 26294704›Full record

ArticleSchizophrenia bulletin2016

Inflammatory Markers in Recent Onset Psychosis and Chronic Schizophrenia.

Faith Dickerson, Cassie Stallings, Andrea Origoni, Jennifer Schroeder, Emily Katsafanas, Lucy Schweinfurth, Christina Savage, Sunil Khushalani, Robert Yolken

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Schizophrenia bulletin, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 4 pooled it
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 4 syntheses or guidelines pooled it, 80 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Faith DickersonThe Stanley Research Program at Sheppard Pratt, Baltimore, MD; fdickerson@sheppardpratt.org.
Cassie StallingsThe Stanley Research Program at Sheppard Pratt, Baltimore, MD;
Andrea OrigoniThe Stanley Research Program at Sheppard Pratt, Baltimore, MD;
Jennifer SchroederSchroeder Statistical Consulting, Ellicott City, MD;
Emily KatsafanasThe Stanley Research Program at Sheppard Pratt, Baltimore, MD;
Lucy SchweinfurthThe Stanley Research Program at Sheppard Pratt, Baltimore, MD;
Christina SavageThe Stanley Research Program at Sheppard Pratt, Baltimore, MD;
Sunil KhushalaniThe Stanley Research Program at Sheppard Pratt, Baltimore, MD;
Robert YolkenThe Stanley Neurovirology Laboratory, Department of Pediatrics, Johns Hopkins School of Medicine, Baltimore, MD.
Sheppard Pratt Health System · USJohns Hopkins Medicine · USStatistical Research (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundImmune markers have been associated with schizophrenia, but few studies have examined multiple markers in both recent onset and chronic schizophrenia patients.

methodsThe sample of 588 individuals included 79 with recent onset psychosis, 249 with chronic schizophrenia, and 260 controls. A combined inflammation score was calculated by principal components factor analysis of the levels of C-reactive protein, Pentraxin 3, and IgG antibodies to gliadin, casein, and Saccharomyces cerevisiae measured in blood samples. Inflammation scores among groups were compared by multivariate analyses.

resultsThe chronic schizophrenia group showed significant elevations in the combined inflammation score compared with controls. The recent onset group surprisingly showed a reduction in the combined inflammation score. Consistent with these findings, the chronic schizophrenia group had significantly increased odds of a combined inflammation score greater than the 75th and the 90th percentile of that of the controls. The recent onset group had significantly increased odds of a combined inflammation score less than the 10th and the 25th percentile level of the controls.

conclusionsThe recent onset of psychosis may be associated with inherent deficits in innate immunity. Individuals later in the course of disease may have increased levels of innate immunity. The reasons for these changes are not known with certainty but may be related to compensatory increases as the disease progresses. Longitudinal studies are needed to determine the course of immune abnormalities in schizophrenia and their role in the clinical manifestations of the disorder.

Indexed as

AdolescentAdultAgedAntibodiesAntibodies, FungalBiomarkersCase-Control StudiesCaseinsChronic DiseaseC-Reactive ProteinFemaleGliadinHumansImmunoglobulin GInflammationMaleAntibodiesAntibodies, FungalBiomarkersCaseinsC-Reactive ProteinGliadinImmunoglobulin GPentraxinsSerum Amyloid P-Componentimmunityinflammationpsychosisschizophrenia

Identifiers

PMID26294704
PMCPMC4681560
OpenAlexW2214944552

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.